Roule Vincent, Ardouin Pierre, Blanchart Katrien, Lemaitre Adrien, Wain-Hobson Julien, Legallois Damien, Alexandre Joachim, Sabatier Rémi, Milliez Paul, Beygui Farzin
Department of Cardiology, Caen University Hospital, Avenue Cote de Nacre, 14033, Caen, France.
Crit Care. 2016 Nov 5;20(1):359. doi: 10.1186/s13054-016-1530-z.
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy in patients with ST-elevation myocardial infarction (STEMI), but its benefit over prehospital fibrinolysis (FL) is not clear.
We performed a systematic review and meta-analysis of randomized controlled trials in which outcomes of patients with STEMI managed with FL early in the prehospital setting versus PPCI were compared.
Compared with PPCI, FL was consistently associated with similar rates of short-term (30-90 days) death (relative risk [RR] 0.94, 95 % CI 0.67-1.31) and cardiovascular death (RR 0.95, 95 % CI 0.64-1.4), a decreased risk of cardiogenic shock (RR 0.67, 95 % CI 0.48-0.95), and an increased risk of any stroke (RR 3.57, 95 % CI 1.39-9.17) and hemorrhagic stroke (RR 4.37, 95 % CI 1.25-15.26). FL was also associated with similar rates of 1-year mortality (RR 1.01, 95 % CI 0.75-1.34) and major bleeding (RR 1.31, 95 % CI 0.96-1.78) in comparison with PPCI, but with a notable level (I index 30.5 % and 59.8 %) of heterogeneity among studies.
Our study suggests that, compared with PPCI, FL performed in the early prehospital setting is associated with similar mortality rates, lower rates of cardiogenic shock, and higher rates of stroke in patients with STEMI. Although the number of studies comparing the two strategies is relatively low, our results support prehospital FL and transfer to hub percutaneous coronary intervention (PCI) centers as a valid alternative to PPCI, allowing potential limitation of resources allocated to developing proximity 24/7 PCI facilities.
在ST段抬高型心肌梗死(STEMI)患者中,直接经皮冠状动脉介入治疗(PPCI)是首选的再灌注策略,但其相较于院前溶栓治疗(FL)的益处尚不明确。
我们对随机对照试验进行了系统评价和荟萃分析,比较了在院前早期接受FL治疗与PPCI治疗的STEMI患者的结局。
与PPCI相比,FL始终与相似的短期(30 - 90天)死亡率(相对风险[RR] 0.94,95%置信区间0.67 - 1.31)和心血管死亡风险(RR 0.95,95%置信区间0.64 - 1.4)相关,心源性休克风险降低(RR 0.67,95%置信区间0.48 - 0.95),以及任何卒中风险增加(RR 3.57,95%置信区间1.39 - 9.17)和出血性卒中风险增加(RR 4.37,95%置信区间1.25 - 15.26)。与PPCI相比,FL还与相似的1年死亡率(RR 1.01,95%置信区间0.75 - 1.34)和大出血风险(RR 1.31,95%置信区间0.96 - 1.78)相关,但研究间存在显著水平(I²指数30.5%和59.8%)的异质性。
我们的研究表明,与PPCI相比,院前早期进行的FL与STEMI患者相似的死亡率、较低的心源性休克发生率和较高的卒中发生率相关。尽管比较这两种策略的研究数量相对较少,但我们的结果支持将院前FL并转运至中心经皮冠状动脉介入治疗(PCI)中心作为PPCI的有效替代方案,从而可能限制分配给发展全天候PCI设施的资源。